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Abstract
Objective: To evaluate the expression of BCL-2 and BAD genes in tissues of breast carcinoma and investigate the
relationship between the expression of BCL-2 and BAD in breast cancer cells with chemosensitivity.
Methods: Immunohistochemical technique was used to detect the expression of BCL-2, BAD in 10 normal breast
tissues, 10 breast fibroadenoma tissues, 40 youth human breast carcinoma tissues, 40 menopause human breast
carcinoma tissues. And to detect the expression of ER, PR in 80 human breast carcinoma tissues. 20 Surgical
samples of breast cancer, diagnosed by pathology, were obtained from The First Affiliated Hospital of Chongqing
Medical University. The cancer sample cells were cultured separately in the incubator at 37°C, 5% CO2 in vitro. The
rate of inhibition of cancer cells in 4 kinds of anticancer drugs– Epirubicin Adriamycin (EADM),5-Fluorouracil (5-Fu),
Navelbine(NVB) and Diaminedichloroplatinum (DDP), were assayed by MTT method.
Results: The expression of BCL-2, BAD genes in young human breast carcinoma tissues were lower than that in
menopause human breast carcinoma tissues (P < 0.05). There was a negative correlation between the positive
expression rate of BCL-2 and histologic grade or the lymph node metastasis (P < 0.05). There was a positive
correlation between the expression rates of BCL-2 and of ER, PR (P < 0.05). The expression of BAD had no
relationship with the expression of ER, PR, histologic grade and the lymph node metastasis(P = NS). Sensitivity
rates of 20 breast cancer cells in 0.1 × PPC within 48 h in vitro were 30% EADM,20% 5-Fu,45% NVB and 25% DDP.
Respectively, the rate of inhibition of EADM,5- Fu, NVB and DDP were significantly higher in the BCL-2 negative
cancer cells than in the BCL-2 positive cancer cells. A negative correlation was found between expression of BCL-2
and chemosensitivity for all the 4 anticancer drugs. The inhibition rates of EADM and NVB were significantly lower
in the BAD negative cancer cells than in the BAD positive cancer cells. A positive correlation was found between
expression of BAD and chemosensitivity for Epirubicin.
Conclusion: The expression of BCL-2 and BAD can be used as prognosis factors of breast cancer. Detection of the
BCL-2 protein expression level, particularly, combined with the detection of the expression of BCL-2 and BAD as
well as ER and PR were helpful in confirming the prognosis of breast carcinoma. The combined detection of BCL-2
and BAD may be markers for predicting the responses to anticancer drugs.
Background
Breast carcinoma is endangering the health of women,
its development process involves decreasing expression
of apoptosis gene. BCL-2 is a anti-apoptosis gene, the
function of BAD gene is promoting the apoptosis of
cell. The balance between BCL-2 and BAD can effect
the apoptosis of cancer cell. In our study, immunohisto-
chemistry was used to detect the expression of BCL-2
and BAD in breast carcinoma, in addition, to analyze
the relationship between the expression of the two
genes and the expression of ER, PR histologic grade,
clinical stage and the lymph node metastasis.
Chemotherapy is an important therapy to breast can-
cer. Although there have been introduced new che-
motherapeutic agents and new chemotherapy, the effect
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important reason for this is that breast cancer cells to
chemotherapeutic agents are neither sensitive nor resis-
tant. Currently looking for the target which could fore-
cast the effect of chemotherapy on breast cancer are
largely needed. The EADM, 5-Fu, NVB, DDP are the
widely-used first-line chemotherapy drugs for breast
cancer in the world. In this study MTT assay was used
to analyze the relative inhibition effect of four kinds of
chemotherapy drugs which include EADM, 5-Fu, NVB
and DDP on breast cancer cells, and the relationship
between the expression of BCL-2, BAD and the
chemosensitivity.
Materials and methods
Materials
1.1.1 We collected 80 samples of breast carcinoma dur-
ing 1998-2002, originated from The First Affiliated Hos-
pital of Chongqing Medical University. Including 40
youth breast carcinoma tissuses(age < 35 years old), 40
menopause breast carcinoma tissuses(age > 60 years
old);11 cases of clinical Stage I, 47 cases of clinical stage
II, 19 patients with clinical stage III, 3 patients with clin-
ical stage IV; histological grade I of 26 cases, 46 cases of
grade II, III is 8 cases. 10 samples from patients of
breast fibroadenoma.10 normal breast tissue samples
from 10 patients of side tissue of fibroadenoma. All the
samples were made into 5 μm tissue sections
1.1.2 We collected 20 fresh samples of breast cancer,
which diagnosed by pathology, without preoperative
radiotherapy and chemotherapy, originated from The
First Affiliated Hospital of Chongqing Medical Univer-
sity. We selected the samples according to the asepsis
operation and avoid the necrosis region. One part of the
tumor specimens was resected from the primary lesions
and transported to our laboratory as quick as possible in
RPMI 1640. The other part was put in formal in fixa-
tion, dehydration and paraffin imbedding.
1..1.3 Reagent
Rabbit anti-human multiclonal BCL-2 antibody and
Rabbit anti-human multiclonal Bad antibody were pur-
chased from Boshide Bio-engineering company. Epirubi-
cin, Fluorouracil, Navelbine and Cisplatin were dissolved
in the mother liquor separately by physiological saline,
and then disposed the mother liquor into fluid (100 ×
PPC), positive pressure filtration sterilization, -20°C
preservation.
1.2.1 Immunohistochemistry
Immunohistochemistry was carried out on 5 μmt i s s u e
sections from paraffin blocks using the avidin-biotin
immunoperoxidase method, The following antibodies
were used: Rabbit anti-human multiclonal BCL-2 anti-
body and Rabbit anti-human multiclonal Bad antibody.
Briefly, the paraffin sections were deparaffinized with
xylene and rehydrated through a series of descending
graded ethanol. Endogenous peroxidase activity was
blocked by incubation for 15 min in 0.3% H2O2 buffer.
To unmask the epitopes of BCL-2 and BAD microwave-
processing pretreatment was carried out in a citrate
buffer, pH = 6.0 for 10 min.. Subsequently, Rabbit anti-
human multiclonal BCL-2 antibody or Rabbit anti-
human multiclonal BAD antibody were applied.
Biotinylated secondary antibody and avidin-biotin-
complex with horseradish peroxidase were applied, fol-
lowed by the addition of the chromogen. Finally, slides
were counterstained with hematoxylin, dehydrated in
ascending ethanol, cleared with xylene, and mounted
with coverslips using a permanent mounting medium.
Result: According to the percentage of the dyeing posi-
tive cells(A), The dyeing positive cell number of zero is
0, <30% is 1, 30%~60% is 2, >60% is 3. According to the
dyeing intensity (B), the achromatic color is 0, the weak
dyeing is 1, the dyeing is 2, the strong dyeing is 3; The
total score (A + B) ≥ 3 divides into the positive expres-
sion, <3 divides into the negative expression. Immuno-
histochemical results to determine criterion-referenced
method of Shimizu [1].
1.2.2 Cell separation, Cell Culture and MTT assay
We adopt mechanical method obtained unicell suspen-
sion. First, washed the specimens with normal saline
(including penicillin 300 μ/ml streptomycin 300 μ/ml)
repeatedly to remove necrotic tissue and blood clots,
put in the aseptic plate, then adding them into a little
culture medium, used eye scissors cut the specimens
into paste, 200 Stainless steel wire grit of 200 mesh
screen was cell suspension, it was obtained by filtering
the minced tissue, though a stainless steel wire grit of
200 mesh screen, checked for the viability and counted,
then centrifuge in 1000 r/min, 10 min; regulated the cell
concentration into 5 × 10
4 /l by RPMI1640(containing
fetal calf serum, penicillin 100 μ/ml streptomycin 100 μ/
ml), vaccinated the cell in 96-well microtiter plates,
180 μl per well; Each well joined chemotherapeutic
agent 20 μl separately (drug level: 10 × PPC, 1 × PPC,
0.1 × PPC), each level set up 3 duplicate holes; Simulta-
neously set up the cell control group and the blank con-
trol group.
Then, the plates were incubated at 37°C in a humidi-
fied atmosphere containing 5% CO2 for 48 h. After
incubation, 20 μl MTT solution was added to each
well, and the plate was incubated for 4 h again; Added
DMSO 200 μl, The absorbance of each well was deter-
mined in the same manner as used in the MTT assay.
The inhibition rate was calculated by using the formula
inhibition rate(IR, %) = (1-mean absorbance of the
treated wells/mean absorbance of the control wells) ×
100%.
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The experimental result indicated by the mean ± stan-
dard deviation(x¯ ± S), used the SPSS11.5 statistics soft-
ware analysis system to carry on the c
2-test, and the T-
test used for categorized variables and the Spearman
rank used for continuous variables correlation analysis.
It is considered to be statistically significant difference
when P < 0.05.
Results
2.1.1 The expression of BCL-2, BAD in breast carcinoma,
breast fibroadenoma and normal breast tissues
The expression of BCL-2 and BAD gene in breast carci-
noma tissues were indicated by brown granules, mainly
distributes in the cytoplasma, and non-uniform; The
positive expression of BCL-2 and BAD in breast carci-
noma(Fig 1, 2). The expression rates of BCL-2 were nor-
mal breast tissue(90%), breast fibroadenoma(80%) and
breast carcinoma(61.25%). Compare with the other 2
groups, the expression of BCL-2 was higher in breast
carcinoma group, the differences were statistically signif-
icant(P < 0.05) (Table 1).
2.1.2 The expression of BCL-2, BAD in youth and
menopause human breast carcinoma
The expression rates of BCL-2 in youth and menopause
human breast carcinoma were 47.5% and 75%(P < 0.05),
The expression rates of BAD in youth and menopause
human breast carcinoma were 30% and 65%, the differ-
ences were statistically significant(P < 0.05) (P < 0.05).
(Table 2)
Figure 1 The positive immunohistochemical expression of BCL-
2 in breast carcinoma tissue.
Figure 2 The positive immunohistochemical expression of BAD
in breast carcinoma tissue.
Table 1 The expression of BCL-2, BAD in breast
carcinoma, breast fibroadenoma and normal breast
tissue
Total BCL-2 BAD
+ - +(%) + - +(%)
Normal breast tissue 10 9 1 90.00% 8 2 80.00%
Breast fibroadenoma 10 8 2 80.00% 7 3 70.00%
Breast carcinoma 80 49 31 61.25%
a 38 42 47.50%
b
Compare with the other two groups a P < 0.05; b P < 0.05
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BAD and the histologic grade, clinical stage and the
lymph node metastasis in human breast carcinoma
The positive rates of BCL-2 in breast carcinoma histolo-
gic grade I, II, III respectively were 84.61%, 58.69%,
12.50%, the difference have stastistical significance(P <
0.01), The positive rates of BCL-2 in breast cancer histo-
logic grades I, II, III to assume the declining trend, sta-
tistical analysis showed no significant difference (P =
NS). In youth breast cancer histologic grade I, II, III the
positive rates of BCL-2 were 87.5%, 44.4%, 0.0%(P <
0.01), and the rates of BAD were 50.0%, 29.6%, 0.0%
(P = NS). In menopause breast cancer tissues histologic
grade I to III the positive rates of BCL-2 were 88.9%,
73.7%, 0.0%, and the rates of BAD were 61.1%, 68.4%,
33.3% statistical analysis both showed no significant dif-
ference, (P = NS).
The positive rates of BCL-2 and BAD were all showed
declining trend in the clinical TNM stage from I to IV
of youth and menopause breast cancer tissues, but, the
difference has no significance (P = NS).
The positive rates of BCL-2 were 15.8% in the youth
breast cancer tissues had axillary lymph nodes metasta-
sis, the rates were 76.2% which had no axillary lymph
node metastasis(P < 0.01); But the positive rates of BAD
showed no relationship with the axillary lymph nodes
metastasis. In the menopause breast cancer tissues the
positive rates were 20.0% in the axillary lymph nodes
metastasis group and 93.3% in control group(P < 0.01);
The positive rates of BAD also showed no relationship
with the axillary lymph node metastasis in menopause
breast cancer tissues(P = NS) (Table 3).
2.1.4 The relationship between the expression of BCL-2,
BAD and the expression of ER, PR
All the breast cancer tissues in this study, 9 tissues with
the expression of BCL-2 and BAD were positive;In this
9 tissues ER(+)PR(+) of 6 cases(66.7%), ER(+)PR(-) of 2
cases(22.2%), ER(-)PR(+) of 1 case(11.0%), ER(-)PR(-)
was 0, When ER(+)PR(+) the positive co-expression
rates of BCL-2 and BAD were significantly higher than
the other three groups, there were significant differences
(P < 0.05). In the 40 cases tissues with BCL-2(+)BAD(-)
18 cases were ER(+)PR(+)(45.0%),10 case were ER(+)PR
(-) (25.0%),7 cases were ER(-)PR(+),5 cases were ER(-)
PR(-), the difference had no significant difference
(P = NS). There were 22 cases with BCL-2(-)BAD(+),
which including ER(+)PR(+) 6 cases(27.3%), ER(+)PR(-)
7 cases(31.8%), ER(-)PR(+) 8 cases(36.4%), ER(-)PR(+) 1
case(4.5%), the difference also had no significance
(P = NS). There were 9 cases which the co-expression
of BCL-2 and BAD were negative, ER(+)PR(-) was 1
case(11.1%),
ER(-)PR(-) were 8 cases(88.9%), ER(+)PR(+) and ER(-)
PR(+) were all 0;The negative co-expression rates of
BCL-2 and BAD in the ER(-)PR(-) group were signifi-
cantly higher than the other three groups (P < 0.05).
(Table 4)
2.2.1 The Sensitivity Of Breast Cancer Cells To Anticancer
Drugs In Vitro
The mean relative inhibition rate of breast cancer cells
are EADM(69.74 ± 7.67)%, 5-Fu(61.81 ± 9.94)%, NVB
(69.10 ± 8.27)%, DDP(63.27 ± 6.79)% in 10 × PPC. The
numerus are EADM(45.39 ± 11.74)%, 5-Fu(44.56 ±
12.28)%, NVB(48.50 ± 9.96)%, DDP(41.42 ± 4.81)% in
1 × PPC and EADM(27.57 ± 8.94)%, 5-Fu(25.48 ±
8.62)%, NVB(30.35 ± 9.02)%, DDP(25.33 ± 5.65)% in 0.1
× PPC. Along with drug concentrating reduction, breast
cancer cancer cell’s inhibition rate relatively reduces gra-
dually. The sensitivity of breast cancer cells to the
4 kinds of drugs in 0.1 × PPC are as follow EADM 30%,
5-Fu 20%, NVB 45%, DDP 25%(Table. 5).
2.2.2 The Relationship Between The Expression Of BCL-2,
BAD And The Chemosensitivity Of The Breast Cancer Cells
In 0.1 × PPC In Vitro
In the drug sensitivity test in vitro of breast cancer cells
of 4 kinds of chemotherapeutic agents in 0.1 × PPC, the
chemosensitivity and the expression level of BCL-2 are
related, the chemosensitivity of the BCL-2(-) tumor cells
was higher than the BCL-2(+) tumor cells(Table. 6), and
there was a negative correlation between the the expres-
s i o no fB C L - 2a n dt h ec h e m o s e n s i t i v i t yo ft h e4d r u g s
(P < 0.05). In the test the sensitivity to EADM and NVB
were associated with the expression of BAD, The BAD
(+)tumour cells were more sensitivity to EADM and
NVB than the BAD(-)ones(P < 0.05)(Table. 7). and there
was a positive correlation between the the expression of
BAD and the chemosensitivity to EADM and NVB. In
the tumour cells which were BCL-2(-)BAD(+) the che-
mosensitivity to the 4 drugs were higher than the BCL-2
(+)BAD(+)and BCL-2(+)BAD(-)ones. The breast cancer
cells in which BCL-2 and BAD were all positive were
more chemosensitive to NVB than the BCL-2(+)BAD(-)
ones(P < 0.05); In the tumour cells which were BCL-2(-)
BAD(+), BCL-2(+)BAD(-)the chemosensitivity to NVB
was higher than to the other 3 drugs, but there were no
significant differences(P = NS)(Table. 8).
Table 2 The expression of BCL-2, BAD in youth and
menopause human breast carcinoma
Total BCL-2 BAD
+ - +(%) + - +(%)
Youth group 40 19 21 47.5%
a 12 28 30%
b
menopause group 40 30 10 75% 26 14 65%
The two groups compare with each other: a P <0 . 0 5bP < 0.05
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BCL-2 is a gene of anti-apoptosis, the mechanism is
possibly related to affect Ca2+ entering the cell, thereby
regulating the signal transduction in the cells[2]. BAD
and BCL-2 are all members of BCL-2 gene family, and
the role of BAD is to promote apoptosis, BAD genes
induced apoptosis through to form heterodimers with
BCL-2, thus inhibited the anti-apoptotic role of BCL-2
[3] The researches on gastrointestinal tumors, and kid-
ney tumors have found that high expression of BCL-2 of
inhibitor of apoptosis, induced tumor growth acceler-
ated, the poor prognosis and poor response to treatment
[4,5]. In this study we find that the expression of BCL-2,
BAD in tissues of breast carcinoma are significantly
lower than tissues of normal breast and tissues of breast
fibroma.
Compared with menopause breast carcinoma, youth
breast carcinoma shows higher malignant degree, the
invasion is stronger, the transfer rate is higher, the prog-
nosis is worse [6]. In this study we found that the
expression rates of BCL-2 and BAD in tissues of youth
breast carcinoma were significantly lower than in the
tissues of menopause breast carcinoma. In breast cancer
histologic grade I to III the expression of BCL-2
assumed the decreasing tendency, the differences had
significant difference, the expresses of BAD during this
process also gradually reduced. The expression of BCL-2
in breast cancer tissues with axillary lymph node metas-
tasis were significantly lower than that without lymph
node metastasis. The expression of BAD in the tissues
of breast carcinoma and axillary lymph node metastasis
showed no correlation obviously, the expression of BCL-
2 and BAD were no significant difference in the clinical
TNM staging of breast carcinoma. The above data
showed that the expression of the two genes played an
important role in the occurrence and development of
the breast carcinoma; and the changes of BCL-2 and
BAD occured in the early stage of the breast carcinoma.
This study showed that the expression of BCL-2 and
the expression of ER and PR were highly correlated. In
the ER and PR-positive groups, the expression of BCL-2
was significantly higher than that of its negative group;
But the expression of BAD showed no significant corre-
lation with the expression of ER and PR. Compare with
the BCL-2 negative group, the expression Of ER and PR
were higher in the BCL-2 positive group. When the
expression of BCL-2 and BAD were positive, at the
same time the expression of ER and PR were especially
high. Milella [7]. also confirmed that the expression of
B C L - 2w a sr e g u l a t e db ye s t r o g e n .T h ee x p r e s s i o no f
BCL-2 most confined to the ER-positive breast cancer
cells, ER-positive was a necessary condition in endocrine
therapy; the patient with BCL-2 high expression having
a good prognosis, maybe more sensitivity to endocrine
therapy. The expression of BCL-2 and BAD can be used
as prognosis factors of breast cancer. Detecting the
Table 3 The relationship between the expression of BCL-2, BAD and the histologic grade, clinical TNM stages and the
axillary lymph nodes metastasis in youth and menopause breast cancer tissues
Total Histologic grade Clinical TNM stage Axillary lymph nodes
I II III I II III IV Positive Negative
Youth breast cancer tissues 40 8 27 5 6 25 8 1 19 21
BCL-2+ 19 7 12 0 4 12 3 0 3 16
BCL-2- 21 1 15 5 2 13 5 1 16 5
+% 47.5% 87.5%
1 44.4% 0.0% 66.7%
3 48.0% 37.5% 0.0% 15.8%
4 76..2%
BAD+ 12 4 8 0 2 8206 6
BAD- 28 4 19 5 4 17 6 1 13 15
+% 30.0% 50.0%
2 29.6% 0.0% 33.3%
3 32.0% 25.0% 0.0% 31.6%
5 28.6%
Menopause breast cancer tissues 40 18 19 3 5 22 11 2 10 30
BCL-2+ 30 16 14 0 4 17 8 1 2 28
BCL-2- 10 2 5 3 1 5318 2
+% 75.0% 88.9%
2 73.7% 0.0% 80.0%
3 77.3% 72.7% 50.0% 20.0%
4 93.3%
BAD+ 25 11 13 1 4 15 6 0 5 20
BAD- 15 7 6 2 1 7525 1 0
+% 62.5% 61.1%
2 68.4% 33.3% 80.0%
3 68.2% 54.5% 0.0% 50.0%
5 66.7%
Compare with each other in the same group:1: P < 0.01,2: P > 0.05,3: P > 0.05,4: P < 0.01,5: P > 0.05
Table 4 The relationship between the expression of
BCL-2, BAD and the expression of ER, PR.
Total ER(+)PR(+) ER(+)PR(-) ER(-)PR(+) ER(-)PR(-)
Bcl-2(+)Bad(+) 9 6(66.7%)
a 2(22.2%)
b 1(11.0%)
c 0(0.0%)
d
Bcl-2(+)Bad(-) 40 18(45.0%) 10(25.0%) 7 (17.5%) 5 (12.5%)
Bcl-2(-)Bad(+) 22 6(27.3%) 7(31.8%) 8(36.4%) 1(4.5%)
Bcl-2(-)Bad(-) 9 0(0.0%) 1(11.1%)
f 0(0.0%)
g 8(88.9%)
h
a compared b.c.d P < 0.05; h comparede.f.g P < 0.05.
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particular the combined detection of the expression of
B C L - 2a n dB A Da sw e l la sE Ra n dP Rw e r eh e l p f u li n
the prognosis of breast carcinoma.
Chemotherapy is an important treatment means of
breast cancer. When we choose chemotherapeutic
agents in clinical there still have certain blindness. By
using the same chemotherapy, the curative effect of dif-
ferent individuals have large difference. If we did not
know the sensitivity of chemotherapeutic agents and uti-
lized them blindly, there would be a lot of side effects.
To avoid the side effects we needed to understand the
sensitivity of chemotherapeutic agents before the che-
motherapy start, and let the treatment individualization.
Therefore, before chemotherapy the drug sensitivity, to
forecast it becomes necessary, especially. Most che-
motherapeutic agents killed tumor cells through indu-
cing apoptosis, thus to investigate the regulatory factor
in the procession of apoptosis will provide us a insight
to know mechanism of the drug resistance.
BCL-2 and the members of this family plays an impor-
tant role in regulating the process of cell apoptosis.
BCL-2 is the anti-apoptotic gene, its mechanism is not
yet clear, and it may affect Ca
2+into cells, thereby reg-
ulating cell signal transduction, disturbing the adversed
function of free radical and so on [8]. The expression
product of BAD can formed heterodimer with the
expression product of the anti-apoptotic members of
BCL-2 gene family, thereby reversed the function of
them. There was clinical research indicating that the
expression level of BCL-2 has positive correlation with
some factors which to benefit the prognosis of breast
cancer such as progesterone receptor and estrogen
receptor, and has negative correlation with the
disadvantage ones such as EGFR and the number of
metastatic lymph node [9]. In the study of breast disease
also found in the procession (normal - simple hyperpla-
sia - atypical hyperplasia - carcinoma in situ - invasive
breast cancer) the expression of BAD had a decreasing
trend [10].
In this study we found that the sensitivity of the
breast cancer cells to the 4 drugs were higher in the
BCL-2 expression negative ones. Through the rank cor-
relation analysis we found that there was a negative cor-
relation between the BCL-2 expression and the
chemosensitivity in breast cancer, indicated that BCL-2
maybe made the breast cancer cells resistant to che-
motherapy drugs through its anti-apoptotic function.
BCL-2 possibly became one of the effect prognosis fac-
tors to determine the curative effect of the chemother-
apy in treatment. In our study the breast cancer cells
with BAD expression positive were more sensitivity to
EADM and NVB than the negative ones. In the tumour
cells which BCL-2(-)BAD(+) the chemosensitivity to the
4 drugs are higher than the BCL-2(+)BAD(+)and BCL-2
Table 5 Sensitivity rate of 20 breast cancer cells to 4 kinds anticancer drugs in 0.1 × PPC
Drugs Desensitize(%) Sensitive(%) Midrange sensitive (%) Sensitivity rate(%)
EADM 70 (14) 30 (6) 0 30 (6)
5-Fu 80 (16) 20 (4) 0 20 (4)
NVB 55 (11) 35 (7) 10 (2) 45 (9)
DDP 75 (15) 25 (5) 0 25 (5)
Table 6 The relationship between the expression of BCL-
2 in breast cancer cells and the relative inhibition ratio
of 4 kinds of anticancer drugs
Drugs BCL-2
+- tP
EADM 30.45 ± 2.52 34.87 ± 2.25 3.99 0.001
5-Fu 30.44 ± 1.49 34.40 ± 2.34 t’ = 4.25 0.001
※
NVB 34.72 ± 3.44 41.19 ± 2.60 4.51 <0.05
DDP 24.32 ± 3.29 29.87 ± 1.90 4.30 <0.05
※T’ -test
Table 7 The relationship between the expression of BAD
in breast cancer cells and the relative inhibition ratio of
4 kinds of anticancer drugs
Drugs BAD
+- TP
EADM 39.95 ± 2.29 28.34 ± 6.67 T’ = 5.78 <0.05
※
5-Fu 30.33 ± 3.90 25.76 ± 4.94 1.998 0.061
NVB 38.60 ± 2.67 26.79 ± 6.42 T’ = 5.67 <0.05
※
DDP 28.70 ± 2.56 26.40 ± 2.44 2.044 0.056
※T’ -test
Table 8 The relationship between the combined
expression of BCL-2 and BAD in breast cancer cells and
the relative inhibition ratio of 4 kinds of anticancer
drugs
Drugs BCL-2(+)BAD
(-)
BCL-2(+)BAD
(+)
BCL-2(-)BAD
(+)
BCL-2(-)BAD
(-)
(n =8 ) ( n =5 ) ( n =6 ) ( n =1 )
EADM 25.93 ± 3.05 33.47 ± 4.65 40.16 ± 5.20 37.72
5-Fu 24.18 ± 4.18 30.38 ± 4.81 37.86 ± 2.80 35.11
NVB 26.06 ± 7.43 36.62 ± 2.78 42.50 ± 2.63 38.88
DDP 23.01 ± 4.14 26.01 ± 4.73 31.90 ± 6.81 28.52
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a n dB A Da r ea l lp o s i t i v ea r em o r ec h e m o s e n s i t i v et o
NVB than the BCL-2(+)BAD(-)ones(P <0 . 0 5 ) .W ei n d i -
cated that the union examination of BCL-2 and Bad
might play a guiding role in the selection of chemother-
apy drugs. Studies [11] confirmed that antisense oligo-
nucleotide of BCL-2 can effectively reduce the
expression of BCL-2 in breast cancer cells, reduced the
inhibition caused by the BCL-2 gene in chemotherapy-
induced apoptosis, improved the treatment effect. Anti-
sense oligonucleotide of BCL-2 as an enhancer of the
chemotherapeutic effect, provided us a new way for the
treatment of breast cancer.
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